Abbott To Present New Data On Next-Generation Drug-Eluting Stent Systems
Abbott will present new data from its SPIRIT family of clinical trials studying the XIENCE V Everolimus Eluting Coronary Stent System, and the ABSORB trial of the world's first fully bioabsorbable drug-eluting coronary stent.
Abbott also will launch The Crossroads Institute at the meeting, an educational institute dedicated to advancing cardiac and vascular medical education to improve patient care.
Late-breaking data presentations from Abbott at EuroPCR 2007 include three-year data from its SPIRIT FIRST trial; a meta-analysis of SPIRIT II and SPIRIT III data that compares the performance of the XIENCE V system to the TAXUS Paclitaxel-Eluting Coronary Stent System; and nine-month data on ABSORB.
Following are Abbott's late-breaking presentations at EuroPCR: